Instead of a traditional IPO, Candid Therapeutics secured a NASDAQ listing and a massive capital infusion by merging with RallyBio. This reverse merger, coupled with a concurrent private investment, provides nearly $700 million in cash to fund operations through 2030, demonstrating a powerful alternative financing path to public markets.

While reverse mergers offer a faster route to public markets, they bypass the extensive investor meetings of a traditional IPO. This can result in a narrowly held story and weaker sell-side coverage, forcing companies to spend 6-12 months post-deal building the investor base they missed.

The path to a successful biotech IPO has changed. The traditional VC-to-public handoff is obsolete. Now, securing pre-IPO investment from public market funds in a 'crossover' round is critical to ensure the offering is oversubscribed and well-received from the start.

Rather than a traditional IPO, QXO acquired a small public company (SilverSun Technologies), appointed Brad Jacobs as CEO, and injected $5 billion of liquidity. This SPAC-like strategy provided immediate access to public markets and a massive capital base for acquisitions.

Biotech firms are increasingly using reverse mergers paired with substantial PIPE financings ($200M+) as an alternative path to the public markets. This "IPO-esque" strategy offers speed and efficiency but may trade off the broader investor exposure gained through a traditional, lengthy roadshow process.

To tap into public market investors, Adaptin Bio merged with a 'Form 10' public shell company. This distinct route is not a SPAC as it doesn't raise money in an IPO. Instead, it provides a faster path to becoming a public reporting entity to attract a wider investor base.

When traditional venture funding dried up for Madrigal Pharmaceuticals, they found an unconventional path to capital and a public listing. They pursued a reverse merger with Cinta, a public company that had recently failed a Phase 3 trial and was seeking an exit. This "bake off" victory secured Madrigal $41 million.

Biotech companies are increasingly favoring reverse mergers over traditional IPOs. The process allows for confidential diligence with select funds, is faster, and sidesteps market volatility like election uncertainty. The previous stigma is fading as the quality of investor syndicates remains high.

For late-stage startups, securing a pre-IPO round led by a premier public market investor like Fidelity is a strategic move. It provides more than capital; it offers a crucial stamp of approval that builds significant confidence and credibility with Wall Street ahead of an IPO.